Ranibizumab for Neovascular Age-Related Macular Degeneration

Abstract
Ranibizumab — a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A — has been evaluated for the treatment of neovascular age-related macular degeneration.

This publication has 20 references indexed in Scilit: